Lindane
Gamene, Kwell, Scabene (lindane) is a small molecule pharmaceutical. Lindane was first approved as Kwell on 1982-01-01. It is used to treat lice infestations and scabies in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lindane
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KWELL | Reed And Carnrick Pharmaceuticals | N-006309 DISCN | 1982-01-01 | 2 products |
| KWELL | Reed And Carnrick Pharmaceuticals | N-010718 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lindane | ANDA | 2020-12-30 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
101 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | — | 1 | 3 | 10 | — | 13 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 1 | 5 | 6 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 1 | 3 | 1 | 5 |
| Neoplasms | D009369 | — | C80 | 2 | — | — | 1 | 1 | 4 |
| Syndrome | D013577 | — | — | 1 | — | — | 2 | 1 | 4 |
| Anesthesia | D000758 | — | — | 3 | — | — | 1 | — | 4 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 1 | 2 | 1 | 4 |
| Nausea | D009325 | — | R11.0 | — | 1 | 1 | 2 | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 2 | 3 |
| Pathologic constriction | D003251 | — | — | — | — | — | 2 | 1 | 3 |
Show 45 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | 1 | 2 | — | — | 6 |
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | 2 | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 3 | — | 1 | 6 |
| Lymphoma | D008223 | — | C85.9 | 3 | — | 1 | — | — | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | 2 | — | — | 4 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | 2 | — | — | 4 |
| Healthy volunteers/patients | — | — | — | 2 | — | 1 | — | — | 3 |
| General anesthesia | D000768 | — | — | — | — | 1 | — | 2 | 3 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | 1 | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | 1 | 2 |
Show 15 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 2 | — | — | — | 2 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | — | 1 |
| Mastodynia | D059373 | EFO_1001366 | N64.4 | — | 1 | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | — | 1 | — | — | — | 1 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | — | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Show 51 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spasm | D013035 | — | M62.83 | — | — | — | — | 3 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 2 | 2 |
| Hot flashes | D019584 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
Show 45 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lindane |
| INN | lindane |
| Description | Beta-hexachlorocyclohexane is the beta-isomer of hexachlorocyclohexane. It has a role as a persistent organic pollutant. It is an organochlorine pesticide and a hexachlorocyclohexane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl |
Identifiers
| PDB | — |
| CAS-ID | 58-89-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL15891 |
| ChEBI ID | 32888 |
| PubChem CID | 727 |
| DrugBank | DB00431 |
| UNII ID | 59NEE7PCAB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lindane
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,443 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lindane
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
167 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use